Read more
2:21 PM · 28 September 2020

Inovio’s stock plunged as COVID vaccine trial is put on hold

-
-
Open account Download free app

Inovio Pharmaceuticals (INO.US) stock tumbled 32% after the company announced that the Phase 2/3 clinical trial for its coronavirus vaccine candidate had been halted while it answered additional questions from the Food and Drug Administration. Company is planning to respond to the FDA in October, and then the agency has 30 days to issue its decision about whether the trial can move forward.

Inovio Pharmaceuticals (INO.US) stock launched today’s session with a bearish price gap and is currently testing major resistance at $11.00 per share which is additionally strengthened by 200 MA (red line). If sellers manage to break below it, a downward impulse towards $6.03 per could be launched. On the other hand, once buyers regain control, the resistance at $16.53 per share may be at risk. Source: xStation5

13 March 2026, 9:27 AM

Adobe Faces AI and Leadership Change. Record Results, Real Challenges

12 March 2026, 12:00 PM

Market wrap: European stocks attempt to stabilize despite the surge in oil prices 🔍

12 March 2026, 9:56 AM

Chubb to insure ships crossing the Strait of Hormuz 🗽 What does it mean for the company?

11 March 2026, 4:40 PM

Rheinmetall earnings: Formidable growth, but the market expected more

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits